UBS keeps USD 135 target for BioNTech stock as results near

Published on 10/27/2026 at 22:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioNTech reports results on November 3, 2026. BioNTech stock costs EUR 77.80 on October 27, 2026, 0.38 percent below the Xetra close.

Analyst target and reporting date

UBS retained its Buy rating and USD 135.00 target on October 26, 2026.
BioNTech will report third-quarter 2026 results on November 3, 2026.
BioNTech stock costs EUR 77.80 at Lang & Schwarz on October 27, 2026, 0.38 percent below the Xetra close.
Second-quarter revenue was USD 105.60 million, down from USD 260.80 million a year earlier.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech SE (ISIN US09075V1026) has a USD 135.00 price target retained by UBS on October 26, 2026, according to MarketScreener. BioNTech will announce its third-quarter 2026 results on November 3, 2026, according to the company's BioNTech release. The stock was trading at EUR 77.80 at Lang & Schwarz on October 27, 2026 at 10:40 p.m. CET, 0.38 percent below the Xetra close of October 27, 2026 at EUR 78.10.

UBS keeps a USD 135.00 target

UBS retained a Buy rating and its USD 135.00 target for BioNTech on October 26, 2026. The target is 54.95 percent above the Nasdaq price of USD 87.06 at 4:00 p.m. EDT on October 27, 2026. That spread leaves the analyst view as the clearest valuation reference ahead of the reporting date.

Revenue fell in the second quarter

BioNTech reported USD 105.60 million in second-quarter 2026 revenue, compared with USD 260.80 million in the second quarter of 2025. The same release showed a GAAP net loss of USD 820.80 million, versus USD 386.60 million a year earlier, as reported by Markets Insider. The figures make the November update important for investors tracking the transition from COVID-19 products toward oncology programs.

What happens on November 3?

The scheduled release will provide the next reported period and a corporate update at 8:00 a.m. ET. BioNTech's Nasdaq quote was last at USD 87.06 on October 27, 2026, while the 52-week range stood at USD 79.52 to USD 124.00. The current US price was 9.48 percent above the low and 29.79 percent below the high.

Comparison with peers

BioNTech SE: minus 0.38 percent, price-to-earnings ratio minus 11.53, market capitalization USD 21.9 billion.

Moderna (Nasdaq, USD): up 4.59 percent, price-to-earnings ratio minus 26.06, market capitalization USD 83.0 billion.

Pfizer (NYSE, USD): up 0.03 percent, price-to-earnings ratio 39.38, market capitalization USD 169.9 billion.

Trading stays below the Xetra close

BioNTech stock was trading at EUR 77.80 at Lang & Schwarz on October 27, 2026 at 10:40 p.m. CET, 0.38 percent below the Xetra close of October 27, 2026 at EUR 78.10. The further course of trading is shown by the continuously updated real-time quote of BioNTech stock.